Is there any treatment I can take to help ensure that the cancer won’t come back?

In many cancers, people can take additional “insurance policy” treatments to reduce the chance of the cancer coming back. You may have heard of chemotherapy, hormone therapy or radiotherapy as additional (“adjuvant”) treatments for cancer. Past studies indicated that these treatments did not seem to work for patients with kidney cancer. However one study published in 2017 showed benefit for select high-risk patients who took sunitinib for one year. Ongoing study of real-world data will help to determine which patients could benefit from taking sunitinib following surgery and how this approach affects their quality of life and overall survival. In the meantime, patients are encouraged to seek an expert opinion to make a fully informed decision.

Researchers are continuing to study different therapies as an adjuvant treatment in kidney cancer. Current trials in the adjuvant setting are listed in our clinical trials database.

Follow-up after treatment?

All cancer survivors should have follow-up care. Once you have finished your cancer treatment, you will establish a follow-up cancer care plan with your treatment team, which may include seeing a range of health professionals.

In general, kidney cancer survivors usually return to their specialist every three to four months during the first few years after treatment, and once or twice a year after that. At these visits, your doctor will look for side effects from treatment and will check to ensure you cancer has not returned (recurred) or spread (metastasised) to another part of your body. The type of tests will depend upon your stage and grade of kidney cancer.

Like most cancers, the chance of the cancer returning is highest soon after treatment. The longer away from the treatment, the more chance the cancer will not recur. However, your treatment team will want to follow you for some time. In some countries, kidney cancer patients are followed for 5 years following initial surgery. Your patient organisation can refer you to guidelines for follow-up that are specific to kidney cancer in your country or other countries.

Bei einigen Krebsarten haben Patienten eine Art zusätzliche „Versicherung“, um ein Wiederauftreten der Erkrankung zu verhindern – sie können Therapien durchführen, die das Risiko eines Rückfalles reduzieren. So zum Beispiel eine Chemo-, Hormon- oder Strahlentherapie als vorbeugende (“adjuvante”) Behandlung. Bisherige Studien legten nahe, dass diese Behandlungsmethoden bei Nierenkrebs keinen Erfolg versprechen. Im Jahr 2017 wurde jedoch eine Studie veröffentlicht, die zeigte, dass die Einnahme von Sunitinib über ein Jahr, für Patienten der Hochrisiko-Gruppe vorteilhaft sein kann. Laufende Studien mit Daten aus der Praxis sollen nun zeigen, welche Patienten von einer Sunitinib-Einnahme nach einer Operation profitieren könnten und wie sich dieser Ansatz auf ihre Lebensqualität und das Gesamtüberleben auswirkt. .

Außerdem geht die Forschung auf diesem Gebiet weiter: Weltweit versuchen Wissenschaftler neue Ansätze für eine adjuvante Therapie bei Nierenkrebs zu finden. Aktuelle Studien dazu sind in unserer Datenbank für klinische Studien aufgeführt.

 

More from the InfoHUB